Adjuvant Nivolumab Approved for Resected Esophageal and GEJ Cancer

The FDA has granted approval to nivolumab (Opdivo®, Bristol Myers Squibb) for patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease after prior neoadjuvant chemoradiotherapy. "No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer," wrote the investigators of the phase 3 CheckMate 577 trial...
Continue reading

FDA Approves Nivolumab With Chemotherapy for Gastric and Esophageal Cancer

The FDA has granted approval to nivolumab (Opdivo®, Bristol-Myers Squibb Company) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the initial treatment of patients with advanced/metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. "Standard first-line chemotherapy options for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric cancer/gastroesophageal junction cancer result in poor overall su...
Continue reading

Advanced Esophageal Cancer: High Risk of Venous Thromboembolic Events During Preoperative Therapy

An exploratory analysis of data from a phase 3 trial observed a high incidence of venous thromboembolic events (VTEs) in patients with locally advanced resectable esophageal cancer undergoing preoperative chemotherapy and chemoradiotherapy, especially in patients with adenocarcinoma. The occurrence of VTEs, including deep vein thrombosis and pulmonary embolus, can negatively impact the clinical outcomes of patients receiving cancer treatment, reducing quality of life and increasing the risk of m...
Continue reading

Nivolumab for Esophageal Cancer: An Interview With Ken Kato, MD, PhD

Results from a phase 3 trial show that nivolumab significantly improves overall survival compared with chemotherapy in patients who have been previously treated for advanced esophageal squamous cell carcinoma (ESCC). In this interview with i3 Health, Ken Kato, MD, PhD, explains the results from this study, as well as rationale for using nivolumab in ESCC, safety considerations, and the study's implications for oncology practice. What is the most challenging aspect of treating patients with advan...
Continue reading

Nivolumab Proves Effective in Advanced Esophageal Cancer

According to the results of the phase 3 trial, ATTRACTION-3, nivolumab significantly improves overall survival compared with chemotherapy in patients who have been previously treated for advanced esophageal squamous cell carcinoma. For this study, results of which are published in The Lancet Oncology, researchers enrolled 419 patients from 90 hospital and cancer centers in Denmark, Germany, Italy, Japan, South Korea, Taiwan, the UK, and the USA. Patients with unresectable advanced or recurrent e...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.